Literature DB >> 19196264

Worldwide esophageal cancer collaboration.

T W Rice1, V W Rusch, C Apperson-Hansen, M S Allen, L-Q Chen, J G Hunter, K A Kesler, S Law, T E M R Lerut, C E Reed, J A Salo, W J Scott, S G Swisher, T J Watson, E H Blackstone.   

Abstract

The aim of this study is to report assemblage of a large multi-institutional international database of esophageal cancer patients, patient and tumor characteristics, and survival of patients undergoing esophagectomy alone and its correlates. Forty-eight institutions were approached and agreed to participate in a worldwide esophageal cancer collaboration (WECC), and 13 (Asia, 2; Europe, 2; North America, 9) submitted data as of July 1, 2007. These were used to construct a de-identified database of 7884 esophageal cancer patients who underwent esophagectomy. Four thousand six hundred and twenty-seven esophagectomy patients had no induction or adjuvant therapy. Mean age was 62 +/- 11 years, 77% were men, and 33% were Asian. Mean tumor length was 3.3 +/- 2.5 cm, and esophageal location was upper in 4.1%, middle in 27%, and lower in 69%. Histopathologic cell type was adenocarcinoma in 60% and squamous cell in 40%. Histologic grade was G1 in 32%, G2 in 33%, G3 in 35%, and G4 in 0.18%. pT classification was pTis in 7.3%, pT1 in 23%, pT2 in 16%, pT3 in 51%, and pT4 in 3.3%. pN classification was pN0 in 56% and pN1 in 44%. The number of lymph nodes positive for cancer was 1 in 12%, 2 in 8%, 3 in 5%, and >3 in 18%. Resection was R0 in 87%, R1 in 11%, and R2 in 3%. Overall survival was 78, 42, and 31% at 1, 5, and 10 years, respectively. Unlike single-institution studies, in this worldwide collaboration, survival progressively decreases and is distinctively stratified by all variables except region of the world. A worldwide esophageal cancer database has been assembled that overcomes problems of rarity of this cancer. It reveals that survival progressively (monotonically) decreased and was distinctively stratified by all variables except region of the world. Thus, it forms the basis for data-driven esophageal cancer staging. More centers are needed and encouraged to join WECC.

Entities:  

Mesh:

Year:  2009        PMID: 19196264     DOI: 10.1111/j.1442-2050.2008.00901.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  105 in total

1.  [The current TNM system for gastrointestinal tumors part I].

Authors:  C Wittekind; A Tannapfel
Journal:  Pathologe       Date:  2010-09       Impact factor: 1.011

2.  Prognostic significance of SLC9A9 in patients with resectable esophageal squamous cell carcinoma.

Authors:  Junying Chen; Jing Wen; Yuzhen Zheng; Hong Yang; Kongjia Luo; Qianwen Liu; Ronggui Hu; Zihui Tan; Qingyuan Huang; Jianhua Fu
Journal:  Tumour Biol       Date:  2015-04-03

3.  Prognostic impact of lymph node involvement and the extent of lymphadenectomy (LAD) in adenocarcinoma of the esophagogastric junction (AEG).

Authors:  Leila Sisic; Susanne Blank; Wilko Weichert; Dirk Jäger; Christoph Springfeld; Marcel Hochreiter; Markus Büchler; Katja Ott
Journal:  Langenbecks Arch Surg       Date:  2013-07-26       Impact factor: 3.445

4.  Management of Tracheo- or Bronchoesophageal Fistula After Ivor-Lewis Esophagectomy.

Authors:  R Lambertz; A H Hölscher; M Bludau; J M Leers; C Gutschow; W Schröder
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

5.  Ivor-Lewis esophagectomy with and without laparoscopic conditioning of the gastric conduit.

Authors:  Wolfgang Schröder; Arnulf H Hölscher; Marc Bludau; Daniel Vallböhmer; Elfriede Bollschweiler; Christian Gutschow
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

6.  Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma.

Authors:  Jia Wang; Nan Wu; Qing-Feng Zheng; Shi Yan; Chao Lv; Shao-Lei Li; Yue Yang
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

7.  ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients.

Authors:  J A Ajani; X Wang; S Song; A Suzuki; T Taketa; K Sudo; R Wadhwa; W L Hofstetter; R Komaki; D M Maru; J H Lee; M S Bhutani; B Weston; V Baladandayuthapani; Y Yao; S Honjo; A W Scott; H D Skinner; R L Johnson; D Berry
Journal:  Mol Oncol       Date:  2013-10-28       Impact factor: 6.603

8.  Association of PYGO2 and EGFR in esophageal squamous cell carcinoma.

Authors:  Meysam Moghbeli; Mohammad Reza Abbaszadegan; Moein Farshchian; Mehdi Montazer; Reza Raeisossadati; Abbas Abdollahi; Mohammad Mahdi Forghanifard
Journal:  Med Oncol       Date:  2013-03-03       Impact factor: 3.064

9.  Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort.

Authors:  N K S Cheedella; A Suzuki; L Xiao; W L Hofstetter; D M Maru; T Taketa; K Sudo; M A Blum; S H Lin; J Welch; J H Lee; M S Bhutani; D C Rice; A A Vaporciyan; S G Swisher; J A Ajani
Journal:  Ann Oncol       Date:  2012-12-17       Impact factor: 32.976

10.  Extent of lymphadenectomy in esophageal cancer: how many lymph nodes is enough?

Authors:  Luis J Herrera
Journal:  Ann Surg Oncol       Date:  2010-03       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.